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In mammals there are at least 10 isoforms of diacylglycerol kinases (DGK). All catalyze the
phosphorylation of diacylglycerol (DAG) to phosphatidic acid (PA). Among DGK isoforms,
DGKε has several unique features. It is the only DGK isoform with specificity for a
particular species of DAG, i.e., 1-stearoyl-2-arachidonoyl glycerol. The smallest of all
known DGK isoforms, DGKε, is also the only DGK devoid of a regulatory domain. DGKε
is the only DGK isoform that has a hydrophobic segment that is predicted to form a
transmembrane helix. As the only membrane-bound, constitutively active DGK isoform
with exquisite specificity for particular molecular species of DAG, the functional overlap
between DGKε and other DGKs is predicted to be minimal. DGKε exhibits specificity
for DAG containing the same acyl chains as those found in the lipid intermediates
of the phosphatidylinositol-cycle. It has also been shown that DGKε affects the acyl
chain composition of phosphatidylinositol in whole cells. It is thus likely that DGKε is
responsible for catalyzing one step in the phosphatidylinositol-cycle. Steps of this cycle
take place in both the plasma membrane and the endoplasmic reticulum membrane.
DGKε is likely present in both of these membranes. DGKε is the only DGK isoform
that is associated with a human disease. Indeed, recessive loss-of-function mutations in
DGKε cause atypical hemolytic-uremic syndrome (aHUS). This condition is characterized
by thrombosis in the small vessels of the kidney. It causes acute renal insufficiency in
infancy and most patients develop end-stage renal failure before adulthood. Disease
pathophysiology is poorly understood and there is no therapy. There are also data
suggesting that DGKε may play a role in epilepsy and Huntington disease. Thus, DGKε
has many unique molecular and biochemical properties when compared to all other
DGK isoforms. DGKε homologs also contain a number of conserved sequence features
that are distinctive characteristics of either the rodents or specific groups of primate
homologs. How cells, tissues and organisms harness DGKε’s catalytic prowess remains
unclear. The discovery of DGKε’s role in causing aHUS will hopefully boost efforts to
unravel the mechanisms by which DGKε dysfunction causes disease.
Keywords: diacylglycerol kinase-ε, phosphatidylinositol cycle, lipid acyl chains, atypical hemolytic-uremic
syndrome, re-entrant helix, arachidonic acid, rodents- and primates-specific signatures
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INTRODUCTION
Among the many isoforms and gene-splicing variants of
mammalian DGK, the DGKε isoform is one of the most unique
in its properties. DGKε is the smallest known isoform, it is the
only one with no domain for binding a specific ligand, it is the
only form that has a predicted transmembrane segment, and it is
unique in having specificity for the acyl chain composition of the
substrate. Mammalian DGKs can be divided into 5 types. DGKε
is the only Type 3 isoform (Figure 1).
DGKε may also have a unique functional role in catalyzing
one of the steps in the phosphatidylinositol-cycle (PI-cycle). The
importance of the biological role of DGKε is suggested by the fact
that it is the only DGK isoform that is associated with a human
disease, namely atypical hemolytic uremic syndrome (aHUS).
INTERACTION WITH DIACYLGLYCEROL
Atypical C1 Domains
DGK catalyzes the reaction between DAG and ATP to produce
PA and ADP. The C1 domains of protein kinase C bind DAG
and phorbol esters directly via interactions mediated by select
residues (Colón-González and Kazanietz, 2006). Amino acid
sequence analysis revealed that all mammalian DGKs harbor at
least two segments homologous to the prototypical C1 domain
(Hurley et al., 1997).Multiple teams independently demonstrated
that for most DGKs, these domains do not bind DAG or phorbol
esters (Ahmed et al., 1991; Sakane et al., 1996); [DGKγ (Shindo
et al., 2001, 2003) and DGKβ (Shindo et al., 2003) are notable
exceptions]. Interestingly, some truncated DGKs devoid of all
C1 domains have preserved catalytic activity (Sakane et al.,
1996). Data suggest that DGKε may be unique among these
DGKs: truncation resulted in complete abrogation of 1-stearoyl-
2-arachidonoyl glycerol (SAG) phosphorylation (Tang et al.,
1996). The biological function of these “atypical C1 domains”
(Hurley et al., 1997) remains elusive to this day.
Specificity for DAG with Certain Acyl
Chains
Except for DGKε, all other isoforms of DGK phosphorylate DAG
at rates that are largely independent of the nature of the acyl
chains of DAG (Topham and Prescott, 1999). In contrast, the
reaction catalyzed by DGKε is very sensitive to the acyl chains
displayed by DAG: its peak activity is when the DAG substrate is
SAG (Tang et al., 1996; Pettitt and Wakelam, 1999). The DAG
molecule harboring these specific acyl chains is a critical lipid
intermediate of the PI-cycle (Figure 2). In addition to DGKε,
Abbreviations: aHUS, atypical hemolytic-uremic syndrome; arrb, arrestinβ; CDS,
CDP-DAG synthase (Phosphatidatecytidylyltransferase); DGK, diacylglycerol
kinase; DAG, diacylglycerol; ECS, electroconvulsive shock; ER, endoplasmic
reticulum; GK, glycerol kinase; GPCR, G-protein coupled receptor; HD,
Huntington’s disease; Htt, Huntington protein; MEFs, mouse embryo fibroblasts;
NeoR, neomycin resistant; PA, phosphatidic acid; PI, phosphatidylinositol; PI-
cycle, phosphatidylinositol-cycle; PIP2, phosphatidylinositol-(4,5)-bisphosphate;
PIPn, phosphorylated forms of PI; SAG, 1-stearoyl-2-arachidonoyl glycerol; TH,
tyrosine hydroxylase.
another enzyme that has specificity for lipid substrates with 1-
stearoyl-2-arachidonoyl is CDP-diacylglycerol synthase 2 (CDS2)
(D’Souza et al., 2014). The possible role of these two enzymes
in enriching the lipid intermediates of the PI-cycle is discussed
below. In addition, acyl chain remodeling of phosphatidylinositol
(PI) through the Land’s cycle, also contributes to acyl chain
enrichment (Gijón et al., 2008).
In vitro Detergent-Based Assays
Data supporting DGKε’s exquisite substrate specificity remain
incomplete. In vitro assays used to test its activity all rely on
simultaneous co-solubilization with detergent of DGKε from
cells together with DAG (Epand and Topham, 2007). A recent
report suggests that the detergent used in these assays can
exert a strong influence on the degree of substrate specificity
(Natalini et al., 2013). The use of membrane bilayers in the
form of liposomes would avoid possible artifacts caused by
the presence of detergent and would more closely simulate
a biological membrane. Until now, we have not been able
to develop a liposome-based assay using extracts from cells
overexpressing DGKε. However, we have recently succeeded in
purifying human DGKε, thereby facilitating its incorporation
into liposomes: this will be the first detergent-free enzyme
activity assay for DGKε. We anticipate that the liposome-based
assays will confirm the specificity of DGKε for SAG since
this substrate specificity has also been demonstrated in vivo
(see below) (Rodriguez de Turco et al., 2001; Milne et al.,
2008).
sn-2 Arachidonoyl Specificity
There have been more recent studies showing that the preference
for an arachidonoyl chain in the sn-2 position of DAG is
very specific (Shulga et al., 2011a). The ability of several
species of DAG having a stearoyl chain at the sn-1 position
and a polyunsaturated acyl chain at the sn-2 position to act
as a substrate for DGKε was determined. The activity of
DGKε when presented with 18:0/20:4-DAG was ∼5-fold higher
than 18:0/18:2-DAG, and DGKε is unable to phosphorylate
18:0/22:6-DAG (Shulga et al., 2011a). On the basis of these
results and others, it is clear that maximal activity requires
that the DAG substrate have an arachidonoyl chain (20:4) at
the sn-2 position. We propose that the arachidonoyl group
at the sn-2 position fits into a specific binding site in
DGKε.
sn-1 Stearoyl Specificity
While an arachidonoyl group at the sn-2 position is critical
to DGKε activity by itself, it is not sufficient to make a good
lipid substrate for DGKε. The monoglyceride 2-arachidonoyl-
glycerol is a poor substrate for DGKε, and can even act
as an inhibitor at higher concentrations (Gantayet et al.,
2011). DGKε has essentially no activity in phosphorylating 1-
monoacylglycerol substrates, but it does have 8% of the activity
of SAG in phosphorylating 2-monoacylglycerol. However, this
activity against monoglycerides, is not very different for DGKε
compared with several other mammalian DGK isoforms (Sato
et al., 2016). In addition, changing only the nature of the bond
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FIGURE 1 | Functional domains of DGKε are contrasted to that of prototypical DGKs from the other 4 subtypes. All protein models were drawn to scale
using the Illustrator for Biological Sequences (http://ibs.biocuckoo.org/) (Liu et al., 2015). The proteins are centered around the shared catalytic site (grayed area)
because it is the most conserved feature across subtypes. Features that are unique to DGKε and other DGKs are listed on the right side. Known and/or possible
phosphorylation (Shirai et al., 2012; Mertins et al., 2013; Park et al., 2015) and ubiquitination (Wagner et al., 2011; Komander and Rape, 2012; Mertins et al., 2013)
sites are also displayed (see text and Table 1 for details). If there are more than one documented isoform, the characteristics of isoform 1 were used for each protein.
The accession (and GI) numbers for the proteins illustrated are: DGKε, NP_003638.1 (4503313); DGKα, NP_958853.1 (41872494); DGK δ1, NP_003639.2
(25777596); DGKθ, NP_001338.2 (40806175); DGKζ1, NP_963290.1 (41872522).
FIGURE 2 | The phosphatidylinositol cycle. Enzymes involved in the
catalysis of each step in the cycle are written in a blue oval above the arrow for
the reaction using abbreviations. Each lipid intermediate in the cycle is written
in red. Figure reproduced from Epand (2016).
at the sn-1 position of 1-SAG from an ester to an ether linkage
(1-O-hexadecyl-2-arachidonoyl-sn-glycerol) also yielded a poor
DGKε substrate (Epand et al., 2004).
The length of the fatty acyl chain at sn-1 position
also influences substrate quality: elongation from 18:0 to
20:0 led to reduced DGKε activity (70% from baseline).
On the other hand, DGKε tolerates slightly shorter acyl chains at
the sn-1 position, as DGKε activity was 90% when substituting
18:0 for 16:0 (Lung et al., 2009). Introduction of unsaturation
to the acyl chain at the sn-1 position surprisingly also had
only a small effect on the rate of substrate phosphorylation
by DGKε. Thus, 20:4/20:4-DAG has about 80% the activity
of SAG (Shulga et al., 2011a). Even more striking are the
following observations: when compared to SAG, 18:0/18:2-DAG
and 18:2/18:2-DAG generate respectively∼20% and ∼60% of
the DGKε activity against SAG. Indeed, 18:0 is the optimal
saturated acyl chain for the sn-1 position when the sn-2 position
is occupied by 20:4, but not when the sn-2 position is 18:2 (Shulga
et al., 2011a). Thus, changing the linkage, length, or degree of
saturation of the acyl chain at the sn-1 position of DAG has
substantial effects on substrate kinetics but many different acyl
chains at the sn-1 position result in substrates with substantial
activity. We propose that the acyl chain at the sn-1 position has
an important, albeit less specific, interaction with DGKε that
may indirectly affect the activity of the enzyme. For example,
the fatty acyl chain at sn-1 may modulate a physical property
of the membrane surrounding the enzyme or influence the
depth of insertion of DAG into the membrane. As a result,
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there appears to be a much less stringent requirement for
the acyl chain at the sn-1, compared with the sn-2 position
of DAG.
Catalytic Accessory Domain: Homology to
Lipoxygenase Sequence
We have shown that the most hydrophobic segment of DGKε,
which is predicted to bind lipids, can be deleted without loss
of enzymatic activity or specificity (Dicu et al., 2007; Lung
et al., 2009). When searching for an alternative lipid binding
site, we decided to explore a segment of DGKε’s accessory
domain that is homologous to the arachidonic acid binding
site of lipoxygenase (Neau et al., 2009). The finding of such a
homologous substrate binding site between lipoxygenase and
DGKε was unexpected because the reactions catalyzed by these
two enzymes are different, so is the chemical nature of the
arachidonoyl groups of the substrates. Remarkably, no other
mammalian DGK isoform harbors this novel motif, which is
referred to as the “lipoxygenase (LOX)-like motif ” (Shulga et al.,
2011b).
This motif is characterized by a string of residues:
L-X(3−4)-R-X(2)-L-X(4)-G, in which X(n) is n residues of
any amino acid. The critical residues are invariant through
vertebrate evolution for both DGKε and lipoxygenase (Shulga
et al., 2011b). They were identified on the basis that site-
specific mutation results in the loss of enzymatic activity
or arachidonoyl specificity. The most important reduction
of DGKε activity was observed when leucine residues were
substituted with more polar and/or sterically smaller amino
acids; the impact of substitutions with less polar and/or
sterically larger residues was not as dramatic. Most interestingly,
substitution of a single amino acid converted DGKα to a
LOX-motif-containing DGK that exhibited more specificity for
arachidonoyl-containing DAG than unmodified DGKα (Shulga
et al., 2011b).
Most mutations of key residues within DGKε’s LOX motif
resulted in a marked loss in catalytic activity. As a result, accurate
assessment of the role of the LOX motif in directing the specific
activity of DGKε against arachidonoyl-containing DAG species
was challenging. We therefore proceeded to test the impact of
mutating residues adjacent to the LOX motif on DGKε substrate
specificity (D’Souza and Epand, 2012). This region, adjacent
to the LOX motif is a hydrophobic segment contained within
the “accessory domain” of DGKε. Unexpectedly, mutagenesis
of several residues in this region of DGKε, which is also
highly conserved in evolution, had a higher activity toward
SAG when compared to wild-type. SAG was the best substrate
for all mutants tested, followed by 1,2-diarachidonoyl glycerol.
However, each mutant exhibited differences in the relative
activity for different DAG substrates. For example, for the wild
type enzyme the ratio of activity against 1-stearoyl-2-linoleoyl
glycerol vs. SAG is 0.11. However, this ratio ranges from 0.03
to 0.22 for the 5 mutants tested. We conclude that these
mutations perturb the lipid binding site, resulting in either
enhanced or reduced substrate specificity (D’Souza and Epand,
2012).
DGKε PURIFICATION AND STABILITY
Structural Information Is Lacking for DGKε
There is currently no crystal structure available for any
mammalian DGK isoform. Co-crystallization of DGKε with its
substrate would be particularly informative. Altogether, these
data would be invaluable to drive the discovery of isozyme-
specific inhibitors, of which there is only one, for a different
DGK isozyme (Liu et al., 2016). However, to do so requires a
robust method for expressing and purifying large quantities of
DGKε. In our hands, determining the optimal expression system
has proven challenging. While bacteria express high levels of
recombinant human DGKε, the enzyme recovered is not useful
since it is inactive. Human DGKα was successfully expressed in
yeast (Abe et al., 2003), but our attempts to express DGKε in the
yeast Pichia were not successful.
We recently showed that insect (Sf21) cells are excellent
bioreactors to produce high amounts of active recombinant
DGKε (Prodeus et al., 2013).We recently succeeded to purify full-
length and truncated (140) human DGKε to near homogeneity
using this cell system coupled to Nickel-affinity chromatography
(Jennings, 2016). In vitro testing confirmed that both forms
retained DGKε’s substrate acyl chain specificity.
Asmentioned in the Section Integral vs. PeripheralMembrane
Protein, DGKε contains a putative membrane-spanning alpha
helix at its N-terminus (Decaffmeyer et al., 2008). DGKε proteins
generated using our protocol were instrumental in allowing us to
test various hypotheses about the role of DGKε’s amino terminus
in binding to membrane lipids and its relevance to the overall
activity and stability of the enzyme (Jennings, 2016).
Glycerol Stabilizes Purified DGKε and
DGKε140 Structure
Circular dichroism analysis of purified DGKε and DGKε140
in solution shows that truncating the N-terminal α-helix does
not impact the secondary structure of DGKε. Both forms of
recombinant DGKε were noted to be highly unstable, losing
enzymatic activity and secondary structure in a period of
hours after purification. Experiments aimed at monitoring
temperature-dependent loss of secondary structure indicates
that both constructs undergo a biphasic transition from folded
to unfolded states, with transitions occurring at ∼56◦C and
∼77◦C in a buffer containing 20% glycerol. We demonstrated
that adding a high percentage of glycerol to the recombinant
DGKε solutions had dramatic stabilizing effects (Jennings, 2016).
We also showed that glycerol concentrations higher than 20%
were necessary to facilitate the partial refolding of DGKε and
DGKε140 after thermal denaturation.
Purified DGKε and DGKε140 Are Active
Activity measurements of purified DGKε and DGKε140 reveal
that both constructs retain their acyl chain specificity for
SAG (Jennings, 2016). These studies of activity reveal dramatic
losses in activity following purification at room temperature,
4◦C storage, −80◦C storage, and particularly during cycles
of freezing/thawing. The incorporation of glycerol into the
purification of DGKε as well as during storage dramatically
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reduces but does not eliminate the observed losses in activity
(Jennings, 2016). The absence of the N-terminal hydrophobic
segment does not compromise specific activity in a detergent-
phospholipid mixed micelle system and suggests that there are
additional regions of DGKε that play critical roles in associating
the protein to membranes/micelles. The advancements made
in the purification and stabilization of DGKε and DGKε140
will facilitate novel studies utilizing more biologically relevant
liposome systems.
In contrast to measuring activity in detergent-phospholipid
mixed micelle systems, liposome systems provide insight into
how bilayer properties and specific lipid species affect enzyme
function. A Ca2+-independent, water soluble DGK has been
studied using liposomes (Thomas and Glomset, 1999a,b).
However, DGKα and DGKζ are the only specific mammalian
isoforms to be studied in a liposome-based system (Fanani et al.,
2004). These enzymes were not purified; instead, they were
recovered by salt extraction of cell pellets from mammalian
cells overexpressing the particular DGK isoform (Fanani et al.,
2004). Regardless, the cruder preparation still provided valuable
information regarding the critical role of lipids in altering
the activity and specificity of DGKα (Fanani et al., 2004).
The successful purification of DGKε is facilitating similar
studies in liposomes and will lead to novel findings regarding
the activation/inhibition of this enzyme. Furthermore, the
purification of DGKε is leading the way to more detailed
studies of structure and protein interactions. It is also aiding
the screening process for the discovery of a DGKε-specific
inhibitor.
DGKε HAS A ROLE IN THE PI-CYCLE
The PI-cycle (Figure 2) has important roles in signal
transduction and in lipid synthesis. Metabolic cycles have
particular properties that are intrinsic to their cyclical nature.
The concentrations of the PI-cycle intermediates quickly reach
a steady-state, which then lasts over prolonged periods of time.
The intermediates of the cycle are synthesized at the same
rate that they are utilized and they are continually regenerated
because they are intermediates within a cycle. The only members
of the cycle that are likely to change with time are those that
also are either substrates or products of reactions outside of
the cycle. In general, the intermediates of the cycle, in addition
to being substrates and products of reactions in the cycle, also
function as catalysts for the cycle, since the functioning of the
cycle neither creates nor destroys these intermediates. They
increase the rate of interconversion among intermediates of
the cycle, i.e., the rate at which the cycle “turns.” The PI-cycle
has features that make it different from other metabolic cycles.
First, it requires steps that are in two different membrane
compartments, namely the plasma and endoplasmic reticulum
(ER) membranes (Epand, 2016). DGKε is found in both the
plasma membrane (Decaffmeyer et al., 2008) as well as in the ER
(Kobayashi et al., 2007), targeted by the amino-terminal segment
of DGKε (Matsui et al., 2014). Second, the lipid intermediates
of the cycle are normally highly enriched with very specific
lipid species that harbor 1-stearoyl-2-arachidonoyl fatty acyl
chains.
It is interesting to note that DAG produced by phospholipase
C-catalyzed hydrolysis of phosphatidylinositol-(4,5)-
bisphosphate (PIP2) is highly enriched with SAG (Pettitt
and Wakelam, 1999). This is peculiar because cell membranes
contain many other types of DAG. SAG phosphorylation to
PA catalyzed by DGKε is one of the key steps of the PI-cycle.
It is followed by a series of conversions that ultimately lead to
the synthesis of PI in the ER. This pathway includes another
1-stearoyl-2-arachidonoyl-specific enzyme, CDS2 (D’Souza and
Epand, 2014). Since the other enzymatic reactions of the PI-cycle
have no effect on the fatty acid chains, all intermediates share the
1-stearoyl-2-arachidonoyl backbone.
PI from DGKε-null cells contain less arachidonic acid (Milne
et al., 2008) and stearic acid (Lung et al., 2009) than control cells.
These data suggest a critical role for DGKε in determining the
acyl chain composition of cellular phosphoinositides. Of interest,
PI is much more affected than PA when taking into consideration
changes in the acyl chain composition (Milne et al., 2008). This is
a remarkable finding since PA is the direct product of the reaction
catalyzed by DGKε. In contrast to normal cells, many cancer
cells do not exhibit enrichment with 1-stearoyl-2-arachidonoyl-
containing PIs, but rather are enriched with somewhat shorter
and less unsaturated acyl chains (Naguib et al., 2015; Kimura
et al., 2016). Differences between the PI-cycles of normal and
cancer cells have yet to be thoroughly investigated: we anticipate
that the activity of other DGKs and/or CDS enzymes must
supplant that of DGKε/CDS2 during oncogeny (Epand, 2016).
The fact that patients with complete DGKε deficiency do not
appear to have increase cancer risks suggests that this mechanism
is unlikely to be a primary driver (See Section Relationship to
Disease).
DGKε DEFICIENCY INCREASES
INCORPORATION OF GLYCEROL INTO
LIPID
Recent studies suggest that DgkE−/− mouse embryonic
fibroblasts (MEFs) incubated with 3H-glycerol exhibit increased
glycerol incorporation into various glycerolipids (Shulga et al.,
2013). Preliminary studies from our laboratory suggest that this
finding is likely due to increased glycerol kinase (GK) expression
in Dgkε−/− MEFs (So et al., 2016). We also found that these
cells also consistently exhibit higher than normal p53 levels (So
et al., 2016). We investigated this tumor suppressor in more
detail because it is known to regulate GK expression (Goldstein
et al., 2013). We thus propose that normally, DGKε is a negative
regulator of glycerol incorporation through GK, via modulation
of p53. In addition, p53 has been shown to exhibit various
interactions with lipids. Links to p53 are likely to be complex
since it also exhibits strong electrostatic interactions with lipids
such as cardiolipin, phosphatidylglycerol, and PA in vitro (Li
et al., 2010; Goldstein et al., 2013). In addition, its translocation
from the nucleus to the mitochondria is modulated by CDS2
(the PI-cycle enzyme mentioned earlier) (Li et al., 2010). Finally,
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mutations in p53 have been linked to alterations in the acyl
chain composition of PI species in a number of cell cultures of
human and mouse origin (Naguib et al., 2015). Since p53 has
many well-studied anti-tumorigenic roles in cells, DGKε-specific
inhibitors may be useful as potential anti-cancer treatments.
Such therapy would be expected to be most efficacious to treat
p53-dependent brain cancers since DGKε is highly expressed
in brain tissue (Shulga et al., 2011c). However, further studies
are required to fully understand how DGKε interacts with p53,
and how such an interaction might contribute to or prevent the
progression of cancer.
INTEGRAL VS. PERIPHERAL MEMBRANE
PROTEIN
Membrane proteins are classified as peripheral or integral, based
on their ease of extraction from a membrane. This empirical
definition, which is based on experimental observations, is
somewhat arbitrary since there is no fundamental difference
between these two classes of membrane proteins. In reality,
data suggest a continuum of small changes between peripheral
and integral membrane-associated proteins. In many respects
DGKε is an example of a protein that displays properties that
are intermediary between these two protein types. For example,
solubilization of overexpressed DGKε did not occur at neutral
pH but partial solubilization occurred at alkaline pH (Dicu
et al., 2007). It is well-known that varying the pH from neutral
to alkaline should have no effect on the extraction of integral
proteins from membranes (the structure of the membrane is
unaffected by this change). Depending on the context, DGKε
proteins may thus exhibit properties that are expected of integral
or peripheral membrane proteins.
A number of predictive algorithms suggest that DGKε
residues 20–40 can form a transmembrane helix (Glukhov et al.,
2007; Jennings et al., 2015). DGKε is the only mammalian DGK
isoform with such a putative transmembrane segment. DGKε is
also predicted to be the only DGK isoform that is permanently
associated with the membrane (Glukhov et al., 2007). Several
experimental lines of evidence support this hypothesis. First, a
model peptide derived from this DGKε segment, flanked with
strings of positively charged lysine residues, was shown to interact
with anionic membranes (Glukhov et al., 2007). Third, during
synthesis of the protein, glycosylation sites at the amino terminus
of DGKε are exposed to the lumen of the ER (Nørholm et al.,
2011). These data strongly support the notion that DGKε’s
hydrophobic segment can form a bona fide transmembrane helix
in cells.
However, in silico calculations suggest that this hydrophobic
segment has two possible stable conformations when associated
with a membrane: a classic transmembrane helix or a U-shaped,
re-entrant helix that enters and leaves the membrane on the
same side of the bilayer (Decaffmeyer et al., 2008). If the
hydrophobic segment is transmembrane, parts of the amino
terminus of DGKε would be expected to be exposed to
the extra-cellular environment (Figure 3). We tested for this
possibility by using a DGKε construct with a FLAG-tag added
to the amino terminus. We reasoned that immunofluorescence
detection of FLAG-DGKε in non-permeabilized cells should
only be possible if the amino terminus crosses the plasma
membrane. We showed that permeabilization was required for
visualization of FLAG-DGKε, strongly suggesting that DGKε
forms mostly re-entrant helices (Decaffmeyer et al., 2008).
Interestingly, FLAG-DGKε was detected in non-permeabilized
cells after Pro33Ala mutagenesis; this proline residue is predicted
to be key to form the U-shaped re-entrant helix [note that
in earlier papers, such as reference (Decaffmeyer et al., 2008),
we refer to this proline residue as 32, corresponding to its
numbering after cleavage of the N-terminal methionine to form
the mature protein. In the present article residue numbering
includes the N-terminal methionine as residue 1] (Decaffmeyer
et al., 2008). The result also suggests that some DGKε locates
to the plasma membrane. The presence of DGKε at the
plasma membrane was demonstrated by Western blotting of
an affinity-purified plasma membrane fraction from 3T3 cells
that had been transfected with FLAG-DGKε (Decaffmeyer
et al., 2008). Note that this proline residue is invariant in
evolution (See Supplementary Materials), suggesting that it
plays an important functional role, perhaps by allowing facile
interconversion between transmembrane and re-entrant helical
conformations.
There is thus conflicting evidence as to whether the amino
terminal segment of DGKε forms a transmembrane or a
re-entrant helix in cell membranes. Mathematical modeling
reveals that the energy difference between these two distinct
conformations is small (Decaffmeyer et al., 2008). It is thus
possible that one conformation may predominate depending
on the discrete properties of the surrounding lipid bilayer
(e.g., membrane thickness, charge, the intrinsic curvature of the
monolayers, or the presence of specific lipids). Interestingly,
many of these parameters differ significantly when the plasma
and ER membranes are compared. Our results may not
be contradictory, but rather reflect normal comformational
changes dictated by environmental conditions or local topogenic
signals.
DGKε INTERACTOME
No systematic investigation has focused on identifying the array
of proteins that interact with DGKε. The only data available
in that regard are from two studies done in HEK293T cells.
In the first study, the investigators use immunoprecipitation
followed by mass spectrometry (LC-ESI-MS/MS) to delineate
the interactomes of 338 Flag-tagged bait proteins, including
DGKε. They reported that DGKε pulled down several proteins
with no clear links to known DGK biology (see Table 1
for details): CDCA1, NUDC, NUF2, PAICS, PDHA1, SET
(Ewing et al., 2007). The other study used a similar mass
spectrometry-based approach to identify the interactomes
of arrestinβ1 (ARRB1) and arrestinβ2 (ARRB2), which are
important negative regulators of G protein-coupled receptors
(GPCR) (Premont andGainetdinov, 2007). It revealed that DGKε
was associated with both ARRB1 and ARRB2, and that these
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FIGURE 3 | Simple models for the amino terminal segment of DGKε inserted into a membrane either as a bitopic transmembrane helix or as a
monotopic re-entrant helix (Nørholm et al., 2011). This illustration is a modified version of Figure 2 from an article on intracellular protein topogenesis (Blobel,
1980). The approximate position of Pro33, a residue important for the interconversion between these two conformations, is shown. The topological relationships of the
intra and extracellular sides of the membrane bilayer, the location of the C1 domains and of the catalytic site are illustrated.
interactions were not modulated by GPCR activation (Xiao
et al., 2007). In yet another proteome-wide interactome study
performed on liver cell extracts, DGKε was found to interact
with MRPL44, a protein involved in mitochondrial ribosomes
(Table 1).
These data should be considered as weak evidence of
interactions since none of the studies offered independent
experimental confirmation. It would have been reassuring to
see at least one of the ARRBs in the list of DGKε interactors
from the first study given that both studies used the same cells
(HEK293T). No subsequent studies have sought to explore the
physiologic relevance of these potential DGKε partners. Given
DGKε’s presumed regulatory role in the signaling pathway of
PLC-activated by GPCR, the interactions with the ARRBs are by
far the most promising. It is clear that important clues regarding
the functions of DGKε in various mammalian cells could be
gleaned from studies focused on the DGKε interactome. While
the same mass spectrometry-based methodology could be used,
other approaches such as BioID (Roux et al., 2013) should also be
considered.
POST-TRANSLATIONAL MODIFICATIONS
OF DGKε PROTEINS
The extent to which post-translational modifications modulate
DGKε function is yet another area of DGKε biology that is
understudied. While phosphorylation of several DGKs has been
demonstrated experimentally (Shirai et al., 2012), there is no
evidence that it plays a major role in modulating DGKε function.
Two studies that presented comprehensive phosphorylation data
from human samples confirmed that DGKε phosphorylation
levels, if present, must be low (Mertins et al., 2013; Park et al.,
2015).
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TABLE 1 | Data on the possible DGKE interactome abstracted from three proteomics studies.
Bait (OMIM No.) Prey (OMIM No.) Full gene name Other names Known functions
DGKεa (601440) PAICS (172439) Phosphoribosylaminoimidazole carboxylase AIRC Purine biosynthesis
NUDC (610325) Nuclear distribution protein C homolog – Nuclear movement protein that
associates with dynein
CDCA1 (611772) Cell division cycle-associated protein 1 NUF2 Chromosome segregation and the
spindle checkpoint
PDHA1 (300502) Pyruvate dehydrogenase, alpha-1 PDHCE1A, PDHE1A, PDHA Conversion of pyruvate into acetyl-CoA
SET (600960) Suppressor of variegation, enhancer of zeste,
and Trithorax
IGAAD Inhibitor of protein phosphatase 2A
DGKεb (601440) MRPL44 (611849) Mitochondrial ribosomal protein l44 – Mitochondrial ribosome
ARRB1c (107940) DGKε (601440) Arrestin, beta, 1 ARRB1, BARR1 G protein-coupled receptor
desensitization
ARRB2c (107941) DGKε (601440) Arrestin, beta, 2 ARRB2, BARR2 G protein-coupled receptor
desensitization
aHEK 293 cells were transfected with flag-tagged bait (DGKε), followed by immunoprecipitation with anti-Flag antibody. The protein complexes associated with DGKε were analyzed
by Mass spectrometry. DGKε was one of 338 baits (Ewing et al., 2007).
bLiver cells (Wang et al., 2011).
cHEK 293 cells were transfected with flag-tagged bait, followed by immunoprecipitation with anti-Flag anti-body. The protein complexes associated with the bait were analyzed by Mass
spectrometry (Xiao et al., 2007).
Several proteome-wide screens focused on other post-
translational modifications have been published in recent years.
The most striking finding is that two distinct studies uncovered
the exact same ubiquitination site at lysine 357 in human DGKε
(Wagner et al., 2011; Mertins et al., 2013). The cells used
in the studies included HEK293T (human embryonic kidney)
and MV44-11 (acute monocytic leukemia) in one study, and
Jurkat cells (immortalized human T cells) in the other. The
same modification was also found at the homologous murine
locus, at lysine 354 (Wagner et al., 2012). In the mouse, Dgkε
ubiquitination was only observed in proteins extracted from the
brain (other tissues tested that did not express ubiquitinated
Dgkε included heart, liver, kidney and muscles). This remarkable
tissue specificity may be unique to mice since three non-brain cell
types were used for the human studies. The so-called “ubiquitin
code” is known to control a wide array of biological functions,
including enhanced degradation, targeting to specific cellular
location, modulation of function, and regulation of protein-
protein interactions (Komander and Rape, 2012). It will be
important to determine the relevance of ubiquitination at this site
and to determine if tissue- and species-specific patterns exist.
NOVEL SEQUENCE FEATURES OF DGKε
Homologs exhibiting a high degree of sequence similarity
to DGKε are present in most eukaryotic organisms, except
plants, fungi, and some unicellular organisms. Comparison of
DGKε sequences from mammalian species reveals a number of
interesting differences that are specific for particular groups of
animals. For example, the DGKε homologs from the Muroidea
family of rodent species (e.g., rats, mice, hamsters, gerbils;
Catzeflis et al., 1992) contain a conserved 2 amino acid deletion
near the N-terminus, which is not found in the homologs from
other mammals (Figure 4). Conserved inserts and deletions
in protein sequences play important roles in mediating novel
protein-protein or protein-ligand interactions (Akiva et al., 2008;
Singh and Gupta, 2009). Thus, it is likely that this rodent-specific
genetic alteration may also affect the biological function of the
rodent DGKε in some subtle manner. The functional significance
of this alteration may become clearer as the role of the amino
terminus is better understood.
A number of other specific changes seen in the DGKε
homologs are specific for the Catarrhini subdivision of
primates, which includes humans, great apes, gibbons,
and old world monkeys (Figure 5). At positions 147 and
440 in the human DGKε, homologs from the Catarrhini
subdivision contain cysteine and serine residues, respectively,
whereas all other mammalian species have serine/threonine or
aspartate/asparagine at these positions. Another specific change
in the DGKε homologs present at position 48 is a distinctive
characteristic of the old world monkeys (Cercopithecoidea). All
DGKε homologs from the Cercopithecoidea family contain a
leucine in this position instead of the glutamine found in all
other vertebrates. The high degree of specificity of the noted
genetic changes within the indicated groups suggests that these
changes are under strong selection pressure and may thus confer
some as yet unknown biological advantages to DGKε functions
in these primates.
It is of much interest that one of the above noted genetic
changes at position 147 is located within one of the C1 domains
(C1B) of DGKε. These are highly conserved and cysteine-
rich domains that are typically involved in binding of DAG
or phorbol esters (Hurley et al., 1997; van Blitterswijk and
Houssa, 2000; Sakane et al., 2007; Jennings et al., 2015) (however,
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FIGURE 4 | Excerpts from a multiple sequence alignment of DGKε sequences showing two conserved characteristics that are of interest. Protein
sequences of DGKε homologs were obtainedfrom the NCBI database (http://www.ncbi.nlm.nih.gov/) and the conserved characteristics noted here were identified in
their sequence alignment as previously described (Gupta, 2016). The first characteristic (highlighted in pink) consists of a 2 aa deletion in a conserved region of DGKε
that is a unique property of the Muroidea family of rodents, which includes rats, mice and hamsters, but not found in the primates or other mammalian homologs. The
sequence information is shown for all rodents and primate homologs and a limited number of other species. The sequence alignment also shows that the proline
residue present at position 33 in human DGKε, which is implicated in the re-entrant property of the N-terminal helical region, is a conserved property of all vertebrate
DGKε sequences (see also Supplementary Table 1).
see also Section Atypical C1 Domains). As such, they may
play a central role in directing the function of DGKs in cells.
Alignment of the C1B domains for human DGKε and DGKδ
reveals very high degree of sequence homology (Figure 6A).
Based on the structural information for the most predominant
form of DGKδ (Miyamoto et al., 2004), we have created and
optimized a homology model of the C1B domain for human
DGKε (Figure 6B) (Sali and Blundell, 1993; Shen and Sali, 2006;
Xu and Zhang, 2011). The superposition of themodeled structure
with the structure of DGKδ shows very high degree of structural
homology between the two isoforms in the C1B domain and it
also shows the location where the Cys substitution specific for
the Catarrhini subdivision has occurred. It is possible that this
additional cysteine primes the C1 domains to be more avid for
DAG-like substrates. This hypothesis can only be confirmed via
mutagenesis experiments and by solving the crystal structure of
DGKε with its DAG substrate.
Another remarkable finding relates to the near-complete
conservation of the hydrophobic segment (positions 21–42) in
vertebrate species, including the proline residue at position 33.
As discussed in the Section Integral vs. Peripheral Membrane
Protein, this segment is hypothesized to act as a membrane-
associated domain (Jennings et al., 2015). This proline residue
is contained within the very hydrophobic segment near the
amino-terminus of DGKε (see hydropathy plot of Figure 1 in
Jennings et al., 2015). In this scenario, the proline residue at
position 33 plays an important role in the formation of a re-
entrant helix (Decaffmeyer et al., 2008). In vitro experiments
have shown that mutagenesis of this position to alanine results
in higher affinity for membranes via conversion of the re-entrant
helix to a transmembrane helix (26). This suggests that there
might be substantial functional advantage for DGKε to form
a re-entrant helix so as to restrict its interactions with lipid
bilayers to the inner leaflet. The sequence alignment of DGKε
from various vertebrate species (mammals, amphibians, reptiles,
birds, and fishes) and also some invertebrates shows that the
proline at position 33 is completely conserved and invariant
in all examined species (see Supplemental Figure 1). This in
turn suggests that the re-entrant potential of this hydrophobic
segment is an evolutionarily conserved property of the DGKε
from different species.
IN VIVO EVIDENCE FROM DGKε
KNOCK-OUT MOUSE
A Dgkε-null mouse was reported in 2001 by investigators that
were studying the role of DGKs in the brain (Rodriguez de Turco
et al., 2001). No major anomalies were noted despite extensive
phenotyping that mostly focused on the neurological system
(Rodriguez de Turco et al., 2001). Quantitative phospholipid
studies on brain tissue from the Dgkε-null mice revealed deficits
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FIGURE 5 | Excerpts from multiple sequence alignment of DGKε sequences showing three conserved sequence polymorphisms that are specific for
different groups of primates. All of the sequences were downloaded from the NCBI database and the sequence alignment to identify conserved characteristic was
carried out as in earlier work (Gupta, 2016). The two sequence polymorphisms (highlighted in blue) are specific for the Catarrhini subdivision of primates, which
includes humans, great apes, gibbons, and old world monkeys. The third polymorphism marked in green is specific for the Cercopithecoidea family, comprising of the
old-world monkeys. Sequence information is shown for all primate homologs and for representative species from other vertebrate groups.
in arachidonic-acid containing PIP2, but no change in DAG
or PA (Rodriguez de Turco et al., 2001). Similar studies in
fibroblasts derived from these mice revealed a similar pattern
(Milne et al., 2008). In vitro corroboration of these results with
RNA interference has not been reported.
While exon 1 was unquestionably replaced by a neomycin
resistance cassette in these mice (Rodriguez de Turco et al., 2001),
it is important to acknowledge that absence of Dgkε protein
has never been specifically demonstrated. The main reason for
this omission is the poor performance of anti-murine Dgkε
antibodies when used to detect endogenous Dgkε with Western
blotting or tissue staining. It was also thought that even if made,
this truncated version of DGKε, which would lack both C1
domains (tDGKε), would be unlikely to be functional (although,
as mentioned in the Section Atypical C1 Domains, the role of
these C1 domain remains unclear). Data obtained with another
truncated DGKε (DGKε1, lacking the segment from Pro6 to
Pro188) showed that such a truncated protein had no activity
toward SAG (Tang, 1999). Of note, DGKε1 activity toward other
DAG substrates was not tested.
Now that work on Dgkε-null mice has potential health-related
ramifications (for patients with DGKε-associated nephropathy,
See Section Relationship to Disease), it is critical to determine
if this model accurately reflects true Dgkε-deficiency. Indeed,
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FIGURE 6 | (A) Sequence alignment of the C1B domain from human DGKε with the corresponding region of the DGKδ isoform, whose solution structure has been
determined by NMR (Miyamoto et al., 2004). (B) Superposition of the three-dimensional (3D) structures of the C1B domain of human DGKε (shown in green) with
human DGKδ (shown in cyan). Homology models of the human DGKε were built using the NMR structural information for human DGKδ (PDB ID: 1R79) (Liu et al.,
2015). The first model in NMR was utilized as the template and the structure was generated using MODELLER v 9.15 (Sali and Blundell, 1993). The structural
comparison of the modeled human DGKε with the DGKδ isoform was carried out using PyMol (http://www.pymol.org).
incomplete knockouts have been described before, and the
methodology employed to generate early mouse models often
involved deleting exon 1 (Müller, 1999). According to the
Knockout Mouse Project initiative (KOMP), the critical exon for
DGKε is exon 3, not exon 1. KOMP is a major NIH-sponsored
initiative aimed at making thousands of knockout mice widely
available (Skarnes et al., 2011). Targeting of the critical exon
maximizes the likelihood of generating a true knockout because
this exon must be comprised in all spliced isoforms and, when
deleted, it must create a frameshift mutation.
If expressed, tDgkε produced from a putative alternative start
codon would be missing the C1 domains. Since the function of
these atypical C1 domains is unclear (see Section Atypical C1
Domains), the functional impact of that loss is difficult to predict.
Importantly, the kinase and catalytic accessory domains would
be intact. tDgkε would thus resemble bacterial forms of dgks,
which lack the segment harboring the C1 domains. Just like these
dgks, tDgkε could in principle actively phosphorylate many other
targets besides SAG, including other types of DAG (Walsh et al.,
1990). More concerning however is the possibility that tDGKε
may gain the ability to phosphorylate ceramide (Schneider and
Kennedy, 1973). The cells may thus be simultaneously exposed
to both a loss and a gain of function. The biological consequences
of such a complex system would be challenging to interpret: it
remains an open question whether this is a viable model for a
human disease caused by a “simple” DGKε deficiency. For these
reasons, it is critical to confirm if this mouse model is indeed a
true knockout.
RELATIONSHIP TO DISEASE
Atypical Hemolytic Uremic Syndrome
(aHUS)
Whole-exome sequencing recently uncovered an unexpected link
between homozygous mutations in the gene encoding for DGKε
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FIGURE 7 | Pathologic mutations in DGKE identified in patients with DGKE-associated nephropathy. All published missense or nonsense Dgkε mutations
that are reported in the literature (Lemaire et al., 2013; Ozaltin et al., 2013; Sánchez Chinchilla et al., 2014; Westland et al., 2014; Lee et al., 2015; Mele et al., 2015;
Miyata et al., 2015), as of August, 2016 are overlayed on an illustration of Dgkε and its functional domains (top). Mutations that affect splice sites or result in
insertions/deletions are overlayed onto an illustration of DGKε mRNA with the boundaries of the 11 coding exons (bottom). Mutation names used adhere to the
standard method promulgated by the Human Genome Variation Society (HGVS) for sequence variation nomenclature (http://varnomen.hgvs.org). Single letter codes
for amino acids are used. Abbreviations used: “c.”, cDNA position; fs, frameshift; IVS, intervening sequence (intron); “p.”, protein position.”
and DGKE-associated nephropathy (Lemaire et al., 2013; Ozaltin
et al., 2013). The bulk of mutations are expected to result in
complete loss-of-function (nonsense, splice site, frameshift); no
clustering to any particular domain was observed (Figure 7).
This rare condition is due to recurrent episodes of thrombosis
in the kidney glomeruli microvasculature. The salient clinical
findings are acute renal failure, low platelets, and hemolytic
anemia. On that basis, it is hypothesized that DGKε protein
must play an important role in regulating thrombosis in the
human kidney. This discovery forced experts to reconsider the
pathophysiologic underpinnings of aHUS (Quaggin, 2013). Of
note, a small group of patients with pathogenic DGKEmutations
present with clinical features that resemble more that of another
glomerular disease, membranoproliferative glomerulonephritis
(Ozaltin et al., 2013). Up until then, abnormal activation of the
alternative complement pathway was thought to be invariably
associated with nearly all forms of aHUS (Noris et al., 2012):
the vast majority of aHUS patients harboring DGKE mutations
exhibit no evidence of complement activation (Lemaire et al.,
2013; Ozaltin et al., 2013). Only supportive measures may be
offered to these patients because there are no targeted therapies.
DGKε was originally cloned from human umbilical vein
endothelial cells, but mRNA expression was predominant in
testes (Tang et al., 1996). The discovery of the link between DGKε
and aHUS recently prompted more in-depth investigations
focused on its presumed role in kidney biology. DGKε protein
was shown to be expressed in three cell types that play major roles
in kidney glomeruli, namely endothelial cells, podocytes, and
platelets (Lemaire et al., 2013; Ozaltin et al., 2013). However, the
lack of disease recurrence in patients after kidney transplantation
strongly suggests that platelets, which are produced by the
bone marrow, are unlikely to be central players in the disease
process (Lemaire et al., 2013). The mechanism by which
DGKε deficiency causes thrombosis exclusively in the kidney
remains unclear. Its expression in other vascular beds has
not been investigated. Quantification of key members of the
PI-cycle needs to be assessed specifically in endothelial cells
to determine if DGKε deficiency in this setting also leads to
paucity of PIP2 (see Section DGKε Has a Role in the PI-Cycle).
Experiments done in cultured endothelial cells show that siRNA
knockdown of DGKε was associated with several phenotypes:
endothelial cell increased activation, increase apoptosis and
decreased proliferation (Bruneau et al., 2015). It will be important
to determine if DGKε-null endothelial cells display the same
characteristics because the siRNA knockdown and knockout of
the same gene may yield very different phenotypes (Rossi et al.,
2015).
The generation of an animal model is often very useful to
delineate the biology of human diseases. Since most patients
are expected to have DGKε deficiency, the Dgkε-null mouse
reported in 2001 would be an ideal candidate model. The original
report showed that there were no major abnormalities with these
animals (see Section Post-translational Modifications of DGKε
Proteins; Rodriguez de Turco et al., 2001). The renal phenotype
of this mouse model was recently re-evaluated in more detail:
the animals developed mild signs of renal disease with age (Zhu
et al., 2016). Interestingly, glomerular lesions were noted in
Dgkε-null mice after exposure to doses of nephrotoxic serum
that did not affect wild type littermates (Zhu et al., 2016). Mouse
models of aHUS often require exposure to exogenous triggers to
reveal their pathogenic potential (Pickering et al., 2006; Thurman
et al., 2012; Vernon et al., 2016). Importantly, exogenous factors
are also known to act as triggers in many patients with genetic
forms of aHUS (Kavanagh et al., 2013). Dgkε-null mice may thus
be a promising research tool to further our understanding
of DGKε-associated nephropathy (assuming it is a full
knockout—see Section Post-translational Modifications of DGKε
Proteins).
Data from the recent report focused on the Dgkε-null mice
suggests that DGKε deficiency leads to systemic inability to
induce cyclooxygenase-2 (Cox-2) (Zhu et al., 2016). This enzyme,
which is responsible for inducible production of prostanglandins,
Frontiers in Cell and Developmental Biology | www.frontiersin.org 12 October 2016 | Volume 4 | Article 112
Epand et al. Diacylglycerol Kinase-ε
was previously shown to be decreased in the brains of Dgkε-
null mice after kindling (Lukiw et al., 2005). When exposed
to lipopolysaccharides, wild-type macrophages increase Cox-2
mRNA and protein levels; similar inductions were observed
when wild-type fibroblasts were incubated with interleukin-β
(Zhu et al., 2016). Interestingly, these responses were abrogated
in macrophages and fibroblasts derived from Dgkε-null mice.
Another line of evidence comes from experiments with wild-type
mice treated with the nephrotoxin puromycin aminonucleoside:
animals invariably develop glomerular lesions that lead to
proteinuria. This phenomenon was shown to be accompanied by
robust inductions of Cox-2 expression and urinary prostaglandin
excretion (Zhu et al., 2016). Application of the same protocol
to Dgkε-null mice revealed relative protection against the
proteinuric effects of this toxin, and this effect was correlated with
blunted Cox-2 and prostaglandin responses (Zhu et al., 2016).
How DGKε activity directly modulates Cox-2 expression has yet
to be established. The relevance of these findings to patients with
mutations in DGKε is unclear.
The renal phenotypes induced by the subclinical doses of
nephrotoxic serum or puromycin are now the main distinctive
features of the Dgkε-null mouse model when compared to
control littermates. It is unclear if other organs are affected
because the bulk of these new investigations were focused on the
kidney. While the other Dgk-null animals have no obvious renal
phenotypes at baseline [Dgkα (Olenchock et al., 2006), Dgkβ
(Shirai et al., 2010), Dgkδ (Crotty et al., 2006), Dgkζ (Zhong et al.,
2003), Dgkι (Regier et al., 2005), Dgkη (Isozaki et al., 2016), Dgkθ
(Goldschmidt et al., 2016)] it is important to realize that none of
these models were exposed to these nephrotoxins. It is therefore
not possible to conclude that the renal lesions observed in treated
Dgkε–null mice are specific to this animal model.
Cardiac Hypertrophy and Heart Failure
DGKε is one of the main DGK isoforms expressed in cardiac
ventricles; others are DGKα and DGKζ (Takeda et al., 2001).
This suggests that DGKε may play an important role in the
heart. Decreased DgkE mRNA levels were observed in the
hearts of rats used for modeling left ventricular hypertrophy
(Yahagi et al., 2005) and myocardial infarction (Takeda et al.,
2001). These results did not tease out if this reduction was
a normal compensatory mechanism, or if it was an integral
part of the disease processes. To start addressing this question,
transgenic mice overexpressing DGKε only in the heart were
generated (Niizeki et al., 2008). When subjected to two distinct
protocols known to induce left ventricular hypertrophy in wild
type mice, DGKε-overexpressing mice appeared to be protected
(Niizeki et al., 2008). These findings translated into a substantial
survival advantage: 4 weeks after the procedure, nearly 80% of
DGKε-overexpressing mice were still alive, almost double that of
wild type controls (Niizeki et al., 2008). Investigations of well-
established biological markers of cardiac pathology corroborate
these findings. Upregulation of transient receptor potential
channel-6 (Kuwahara et al., 2006) and increased PKCε and
PKCα translocation (Hahn et al., 2003; Song et al., 2015) were
only observed in wild type mice (Niizeki et al., 2008). Taken
together, these results suggest that increasing DGKε function
may be a promising target to help prevent heart failure and
restore cardiac function. The first step in that direction will be
to determine how relevant these data are to patients with cardiac
dysfunction. If substantiated, the path to DGKε-based therapy
will not be straightforward since it would require tissue-specific
overexpression of DGKε.
Epilepsy and Seizure Susceptibility
High expression of DGKε in brain tissue suggests that it may
play an important role in this organ system (other DGKs are also
high in the brain, including β, γ, and ζ ) (Zhang et al., 2012).
DgkE−/− mice exhibit higher resistance to electroconvulsive
shock (ECS) when compared to control littermates (Rodriguez
de Turco et al., 2001). A role for DGKε in this process was
supported by phosphoinositide quantifications: while wild type
mice displayed increased ECS-induced polyphosphoinositide
(PIPn) degradation and 20:4 DAG formation, DgkE−/− mice did
not (Rodriguez de Turco et al., 2001).
In a similar study, DgkE−/− mice displayed fewer motor
seizures, fewer epileptic events, and rapid behavioral recovery
following brain stimulation compared to wild type mice (Musto
and Bazan, 2006). In addition, wild type mice serially exposed to
multiple small seizure events (kindling) developed typical brain
morphological changes associated with seizures, but these were
absent in DgkE−/− mice (Musto and Bazan, 2006). Kindling
induced upregulation of cyclooxygenase-2 (COX-2) and tyrosine
hydroxylase (TH) gene expression in wild type mice but not
in DgkE−/− mice (Lukiw et al., 2005). High COX-2 expression
has been associated with recurrence of hippocampal seizures
(Takemiya et al., 2003), and repeated seizures lead to increased
TH levels in the brain (Ryu et al., 2000). These data thus suggest
that DGKε regulates seizure susceptibility via modulation of
COX-2 and TH levels in the brain. It is important to acknowledge
that the relevance of these data to humans is unclear as there
are no data linking aberrant DGKε function to patients with
neurological conditions.
Huntington’s Disease
DGKε has been identified as a promising target for treating
Huntington’s Disease (HD) (Zhang et al., 2012). This condition
is characterized by polyglutamine expansion in the N-terminus of
the Huntingtin protein (Htt) that causes significant neuronal loss
in the striatum and cortex (MacDonald et al., 1993; Zhang et al.,
2012). DGK inhibitor II (R59022) was identified as a promising
anti-HD compound in a kinase inhibitor library screen. This in
vitro assay was performed on mouse HD striatal cell model and
the readout was the level of mutant Htt cellular toxicity (Zhang
et al., 2012). More specifically, R59022 inhibited the expected
increase in caspase 3 and 7 activity triggered by serumwithdrawal
(Zhang et al., 2012). Cells expressing mutant Htt were also found
to have lower levels of PIPn, that can be restored upon decreasing
DGK activity (Zhang et al., 2012).
Pinpointing which of the 10 mammalian DGK isoforms
was involved in this process required further testing since this
compound is a non-specific DGK inhibitor (Sato et al., 2013).
siRNA knockdown experiments carried out against the four DGK
isoforms expressed in the mouse striatum showed that only DgkE
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siRNA caused a decrease in caspase 3 and 7 similar to that
observed with R59022 (Zhang et al., 2012). Data from two well-
established in vivomodels support the hypothesis suggesting that
in vivo, enhanced DGKε activity plays a role in HD pathogenesis.
First, expression of DgkE shRNA in a Drosophila HD model
partially rescued the motor impairment induced by Htt (Zhang
et al., 2012). Second, DgkE mRNA levels were higher in the
striatum of a mouse model of HD (Htt overexpression) (Zhang
et al., 2012).
FUTURE PERSPECTIVES
The unique primary structure of the smallest known isoform
of mammalian DGK, as well as the specificity of DGKε for
arachidonoyl-containing DAG, has been known for some time.
However, recent findings have presented the possibility of further
advances of knowledge in the near future. Two developments
have been principally responsible for this. One is the purification
of DGKε that will allow new protein structural and membrane
binding studies that have not been previously possible. There
has also recently been described a causal link between recessive
DGKE mutations and a human disease, atypical hemolytic-
uremic syndrome (aHUS) (Lemaire et al., 2013). This has given
increased importance to defining the biological roles of DGKε in
the normal and diseased state.
Crystal Structure
Up to this time, no isoform of a mammalian DGK has been
crystallized and its structure determined. However, the crystal
structure of a bacterial dgkB from Staphylococcus aureus, has
been determined (Miller et al., 2008). The amino acid sequence
shows 18% identity, with the active site being particularly well
conserved (Jennings et al., 2015). A tentative model for the
folding of DGKε has been made using the crystallographic
structure of dgkB (Jennings et al., 2015).
Lipid Dependence of Membrane Binding
Binding studies of DGKε with liposomes of defined lipid
composition have not yet been carried out because the enzyme
was not available in pure form but only as membrane pellets
from over-expression systems. Now that we have purified DGKε
in solution we can perform such experiments. Dr. Prasanta
Hota has done some initial studies in Dr. Epand’s laboratory
using PIP strips (Echelon Biosciences Inc., Salt Lake City,
Utah). It was found that the binding to PI, phosphatidylcholine
and lysophosphatidylcholine was very weak, binding to
PA, phosphatidylserine, and phosphatidylethanolamine was
intermediate and binding to PI with one, two, or three phosphate
groups added to the inositol ring was very strong. It is known
that phosphorylated forms of phosphatidylinositol are good
inhibitors of DGKε (Walsh et al., 1995). Phosphatidylinositol-
(4,5)-bisphosphate is a noncompetitive inhibitor with respect
to SAG but a competitive inhibitor with respect to ATP (Walsh
et al., 1995). This is not purely an electrostatic effect since
phosphatidylinositol-trisphosphate is a weaker inhibitor of
DGKε than is the diphosphate (Walsh et al., 1995). There is
thus likely to be some specificity in the binding of DGKε to
membranes containing anionic lipids. The effect of anionic
lipids on DGKε binding to membranes has not been fully
assessed.
Activity and Substrate Specificity in
Membrane Bilayers
There is no reported data on the activity of DGKε using an
assay system with phospholipid bilayers. All the reported enzyme
activity studies with DGKε have been done with a detergent-
solubilized system. Phospholipids in liposomes are arranged
as bilayers, which more closely simulates their arrangement
in biological membranes. Even the fundamental property of
arachidonoyl substrate specificity has not been tested in a bilayer-
based system. It also is not clear howmembrane binding relates to
enzymatic activity of DGKε. It is clear that the DAG substrate is
part of the membrane and that DGKε has to bind to a membrane,
at least transiently, for phosphorylation to occur. However, as
indicated by our preliminary data, anionic lipids strengthen the
binding of DGKε to the membrane. Why then don’t anionic
lipids promote the activity of DGKε as they do for other isoforms
of mammalian DGK?
Development of a DGKε-Specific Inhibitor
In order to gain a better understanding of DGKε-related diseases,
isoform-specific inhibitors should be identified and used in
experimental work to delineate the role of DGKε in various
tissues and cell types. Although there are several commercially
available DGK inhibitors, such as R59022 (de Chaffoy de
Courcelles et al., 1985) and R59949 (Sato et al., 2013), there are
currently no isoform-specific DGKε inhibitors.
Traditionally, the activities of DGK isoforms were assessed
using amicelle-based assay, which utilizes detergents to solubilize
lipid components from a lipid film (Epand and Topham, 2007).
The hydrated lipid film is then sonicated to produce small
unilamellar vesicles. The vesicles are used in a radioactive assay
to evaluate the activity of the enzyme, by measuring the transfer
of 32P from [γ-32P]-ATP to DAG to form PA (Epand and
Topham, 2007). Although this procedure is quite insensitive to
non-DGK ATPase activity, the assay might not be well suited for
a high-throughput system due to the extensive radioactive and
extraction procedures.
Recently, an ATP-luciferase system was developed to evaluate
the isoform selectivity of the R59949 and R59022 inhibitors for
various DGKs (Sato et al., 2013). The assay was later optimized
to study DGKα, and was used to identify a novel DGKα-specific
inhibitor, CU-3 (Liu et al., 2016). Similarly, the ATP-luciferase
assay can be optimized to study DGKε in a high-throughput
format to identify a DGKε-specific inhibitor. Due to the fact that
DGKε utilizes ATP as a phosphate donor in the conversion of
DAG into PA, the concentration of ADP generated can be used
as a measure of PA production and enzyme activity (Shulga et al.,
2011c). Since the ATP-luciferase assay detects the ADP released
in the kinase reaction, the assay must utilize purified DGKε, in
order to reduce contamination with other sources of ATPase
activity (Zegzouti et al., 2009).
Once a pool of candidate inhibitors has been identified using
the high-throughput method, the candidates can be validated
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using various assays. For example, the traditional micelle-based
radioactive assay or the liposome based assay currently being
developed can be used to confirm changes in enzyme activity
in the presence of inhibitors (Epand and Topham, 2007). In
addition, a 31P nuclear magnetic resonance assay (NMR) can be
used to identify phosphorous containing substrates and products
and detect potential contaminants with ATPase activity (Prodeus
et al., 2013). Lastly, the ATP-luciferase assay can be optimized
to assess the activity of various other DGK isoforms. Once
optimized, the assay would be used to the test the inhibitory
potential of candidate compounds against various DGK isoforms,
to assess the isoform specificity of novel inhibitors.
The development of a DGKε-specific inhibitor would be
invaluable for studying the role of DGKε in various disease
processes. Specifically, the isoform-specific inhibitor could be
used to recapitulate physiological environments lacking DGKε.
In addition, the luciferase assay holds potential as a diagnostic
tool for measuring the enzyme activity of DGKε in patients
(or with CRISPR-Cas9 mutated cells) with missense DGKε
mutations.
Possible Modulation of DGKε’s
Transmembrane vs. Re-entrant Helix
The amino terminal hydrophobic segment of DGKε is highly
conserved in evolution (Figure 3). In particular, there is an
invariant proline residue at position 33 in human DGKε that
is present at the same position of the aligned sequences from
all DGKε from a range of organisms (Supplementary Materials).
We have shown that this proline residue has an important
role in determining the position of equilibrium between a
transmembrane helix and a re-entrant helix (Decaffmeyer et al.,
2008). This segment of the protein has no effect on the activity or
specificity of DGKε using an in vitro assay in detergent micelles
with N-terminal 40–60 residue deletion mutants. However, we
believe that it is unlikely that this segment of the protein
would not have a biological function. Forming a re-entrant
helix would promote the positive curvature of the monolayer
in which it is present. This could influence the region of
the membrane to which DGKε partitions and/or modulate its
interaction with other proteins. An understanding of the role
of this proline residue and possibly of the interconversion
between re-entrant and transmembrane helix is a theme for
future investigations.
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